Search Results - "Bujas, Maja"

Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial by Leiter, Lawrence A., Cariou, Bertrand, Müller‐Wieland, Dirk, Colhoun, Helen M., Del Prato, Stefano, Tinahones, Francisco J., Ray, Kausik K., Bujas‐Bobanovic, Maja, Domenger, Catherine, Mandel, Jonas, Samuel, Rita, Henry, Robert R.

“…Aims To investigate the efficacy and safety of alirocumab in participants with type 2 (T2D) or type 1 diabetes (T1D) treated with insulin who have elevated LDL…”
Get full text

Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial by Ray, Kausik K., Leiter, Lawrence A., Müller‐Wieland, Dirk, Cariou, Bertrand, Colhoun, Helen M., Henry, Robert R., Tinahones, Francisco J., Bujas‐Bobanovic, Maja, Domenger, Catherine, Letierce, Alexia, Samuel, Rita, Del Prato, Stefano

“…Aim To compare alirocumab, a proprotein convertase subtilisin‐kexin type 9 inhibitor, with usual care (UC) in individuals with type 2 diabetes (T2DM) and mixed…”
Get full text

Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub‐analysis of ODYSSEY COMBO II by Leiter, Lawrence A., Zamorano, José Luis, Bujas‐Bobanovic, Maja, Louie, Michael J., Lecorps, Guillaume, Cannon, Christopher P., Handelsman, Yehuda

“…Aim This sub‐analysis of the ODYSSEY COMBO II study compared the effects of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in…”
Get full text

Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials by Ganda, Om P., Plutzky, Jorge, Sanganalmath, Santosh K., Bujas‐Bobanovic, Maja, Koren, Andrew, Mandel, Jonas, Letierce, Alexia, Leiter, Lawrence A.

“…Aims Individuals with both diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD) are at very high risk of cardiovascular events. This…”
Get full text

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials by Henry, Robert R., Müller‐Wieland, Dirk, Taub, Pam R., Bujas‐Bobanovic, Maja, Louie, Michael J., Letierce, Alexia, Ginsberg, Henry N.

“…Aims This analysis assessed the efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in patients with or without…”
Get full text

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials by Ray, Kausik K., Vallejo-Vaz, Antonio J., Ginsberg, Henry N., Davidson, Michael H., Louie, Michael J., Bujas-Bobanovic, Maja, Minini, Pascal, Eckel, Robert H., Cannon, Christopher P.

“…Elevated lipoprotein(a) [Lp(a)] levels are considered a causal factor for cardiovascular disease. In phase 3 ODYSSEY trials, alirocumab reduced levels of…”
Get full text

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies by Ray, Kausik K, Del Prato, Stefano, Müller-Wieland, Dirk, Cariou, Bertrand, Colhoun, Helen M, Tinahones, Francisco J, Domenger, Catherine, Letierce, Alexia, Mandel, Jonas, Samuel, Rita, Bujas-Bobanovic, Maja, Leiter, Lawrence A

“…Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C),…”
Get full text

Game-based versus traditional case-based learning Comparing effectiveness in stroke continuing medical education by Deanna Telner, Maja Bujas-Bobanovic, David Chan, Bob Chester, Bernard Marlow, James Meuser, Arthur Rothman, Bart Harvey

“…To evaluate family physicians' enjoyment of and knowledge gained from game-based learning, compared with traditional case-based learning, in a continuing…”
Get full text

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk by Müller-Wieland, Dirk, Leiter, Lawrence A, Cariou, Bertrand, Letierce, Alexia, Colhoun, Helen M, Del Prato, Stefano, Henry, Robert R, Tinahones, Francisco J, Aurand, Lisa, Maroni, Jaman, Ray, Kausik K, Bujas-Bobanovic, Maja

“…Type 2 diabetes mellitus (T2DM) is often associated with mixed dyslipidaemia, where non-high-density lipoprotein cholesterol (non-HDL-C) levels may more…”
Get full text

Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels by Roth, Eli M., MD, FACC, Bujas-Bobanovic, Maja, MD, MSc, Louie, Michael J., MD, MPH, MSc, Cariou, Bertrand, MD, PhD

“…Abstract Purpose Clinical trials of the PCSK9 inhibitor alirocumab, an every 2 week injectable monoclonal antibody, have shown significant reductions in…”
Get full text

Improved cardiovascular prevention using best CME practices: A randomized trial by Laprise, Réjean, Thivierge, Robert, Gosselin, Gilbert, Bujas-Bobanovic, Maja, Vandal, Sylvie, Paquette, Daniel, Luneau, Micheline, Julien, Pierre, Goulet, Serge, Desaulniers, Jean, Maltais, Paule

“…Introduction: It was hypothesized that after a continuing medical education (CME) event, practice enablers and reinforcers addressing main clinical barriers to…”
Get full text

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial by Schwartz, Gregory G, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Bujas-Bobanovic, Maja, Diaz, Rafael, Fazio, Sergio, Fras, Zlatko, Goodman, Shaun G, Harrington, Robert A, Jukema, J Wouter, Manvelian, Garen, Pordy, Robert, Ray, Kausik K, Scemama, Michel, White, Harvey D, Steg, Ph Gabriel

“…Abstract Aims Long-term, placebo-controlled cholesterol-lowering trials have demonstrated legacy effects (clinical benefits that persist or emerge after trial…”
Get full text

Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial by Taskinen, Marja-Riitta, Del Prato, Stefano, Bujas-Bobanovic, Maja, Louie, Michael J., Letierce, Alexia, Thompson, Desmond, Colhoun, Helen M.

“…Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9, significantly reduces low-density lipoprotein cholesterol (LDL-C). We…”
Get full text

SHORT-DURATION, VERY HIGH-INTENSITY LIPID-LOWERING THERAPY RESULTS IN PROLONGED REDUCTION OF CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROME by Schwartz, Gregory G., Szarek, Michael, Bhatt, Deepak L., Bittner, Vera, Bujas-Bobanovic, Maja, Diaz, Rafael, Fazio, Sergio, Goodman, Shaun G., Harrington, Robert A., Jukema, Johan Wouter, Pordy, Robert, Scemama, Michel, White, Harvey D., Zeiher, Andreas M., Steg, Philippe Gabriel

Get full text

Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial by Schwartz, Gregory G, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Bujas-Bobanovic, Maja, Diaz, Rafael, Fazio, Sergio, Fras, Zlatko, Goodman, Shaun G, Harrington, Robert A, Jukema, J Wouter, Manvelian, Garen, Pordy, Robert, Ray, Kausik K, Scemama, Michel, White, Harvey D, Steg, Ph Gabriel

“…Long-term, placebo-controlled cholesterol-lowering trials have demonstrated legacy effects (clinical benefits that persist or emerge after trial end). It is…”
Get full text

Short-term educational intervention improves family physicians' knowledge of depression by Kutcher, Stanley, Lauria-Horner, Bianca, MacLaren, Connie, Bujas-Bobanovic, Maja, Karlovic, Zlatko

“…Introduction: Depression is frequently unrecognized and undertreated. Therefore, there is a need to increase the knowledge and skills of primary care…”
Get full text

ALIROCUMAB SAFETY IN INDIVIDUALS WITH AND WITHOUT DIABETES MELLITUS: POOLED DATA FROM 14 ODYSSEY TRIALS by Leiter, Lawrence, Tinahones, Francisco J, Karalis, Dean, Bujas-Bobanovic, Maja, Letierce, Alexia, Samuel, Rita, Jones, Peter

“…Background: Individuals with diabetes mellitus (DM) and elevated low density lipoprotein cholesterol (LDL-C) are at increased cardiovascular risk…”
Get full text

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin by Müller-Wieland, Dirk, Rader, Daniel J, Moriarty, Patrick M, Bergeron, Jean, Langslet, Gisle, Ray, Kausik K, Manvelian, Garen, Thompson, Desmond, Bujas-Bobanovic, Maja, Roth, Eli M

“…Abstract Context In the ODYSSEY CHOICE I trial, alirocumab 300 mg every 4 weeks (Q4W) was assessed in patients with hypercholesterolemia. Alirocumab efficacy…”
Get full text

Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab by Vallejo-Vaz, Antonio J, Leiter, Lawrence A, Del Prato, Stefano, Taskinen, Marja-Riitta, Müller-Wieland, Dirk, Bujas-Bobanovic, Maja, Letierce, Alexia, Mandel, Jonas, Samuel, Rita, Ray, Kausik K

“…Aims Guidelines recommend targeting non-high-density lipoprotein cholesterol to reduce cardiovascular risk. We assessed the impact of baseline triglycerides on…”
Get full text

EFFICACY AND SAFETY OF THE PCSK9 INHIBITOR ALIROCUMAB 300 MG EVERY 4 WEEKS IN INDIVIDUALS WITH TYPE 2 DIABETES ON MAXIMALLY TOLERATED STATIN THERAPY by Müller-Wieland, Dirk, Rader, Daniel, Moriarty, Patrick, Bergeron, Jean, Langslet, Gisle, Ray, Kausik, Manvelian, Garen, Thompson, Desmond, Bujas-Bobanovic, Maja, Roth, Eli

“…Background: Individuals with diabetes and elevated LDL-C are at particularly high risk for atherosclerotic cardiovascular disease…”
Get full text